Abstract
An introductory clinical trial of the anti-oestrogenic agent IC146474 in late or recurrent carcinoma of the breast is described.
Forty-six patients have been treated, of whom 10 have shown a good response. This is of the same order as that seen with oestrogens and androgens.
The particular advantage of this drug is the low incidence of troublesome side effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Cole, M., Jones, C. & Todd, I. A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474. Br J Cancer 25, 270–275 (1971). https://doi.org/10.1038/bjc.1971.33
Issue Date:
DOI: https://doi.org/10.1038/bjc.1971.33
This article is cited by
-
Tamoxifen evolution
British Journal of Cancer (2023)
-
Racial disparities in breast cancer preclinical and clinical models
Breast Cancer Research (2022)
-
Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines
Breast Cancer (2022)
-
Mathematical model for the estrogen paradox in breast cancer treatment
Journal of Mathematical Biology (2022)
-
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
npj Breast Cancer (2022)